Courtney C. Nawrocki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Courtney C. Nawrocki has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Alison F. Hinckley
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA
5 shared publications - Alexandra M. Linz
Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, USA
3 shared publications Sarah A. Hook
Affiliation Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America
3 shared publications- Sarah A. Hook
Centers for Disease Control and Prevention, Division of Vector-Borne Diseases , Fort Collins, Colorado
3 shared publications Alison F. Hinckley
Affiliation Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America
2 shared publications- AmberJean P. Hansen
Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, USA
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0349121
Exploring data-driven algorithms to identify Lyme disease cases in electronic health records
A tool capable of quickly and accurately identifying Lyme disease (LD) cases in endemic areas would have powerful applications in both research and public health. Using data from a single health system in an area with high LD incidence, we evaluated the feasibility and accuracy of data-driven algorithms to accurately identify LD cases based on easily extracted, structured data elements that are available in electronic health records (EHR). We used random forest and decision tree algorithms to explore the importance of various data elements and to investigate how different combinations of data elements accurately classified clinical events as either LD cases or non-cases. The data elements explored included patient demographics, International Classification of Diseases, 10 th Revision, (ICD) codes, LD laboratory tests and their results, and antibiotic prescription orders. Our best performing algorithm was a manually constructed decision tree that incorporated information from three presence/absence variables: an LD ICD code (A69.2x), a positive LD serology test, and a doxycycline order occurring within 30 days of either of the other two elements, which achieved 82% accuracy, 93% sensitivity, 60% adjusted positive predictive value, 68% specificity, and 91% adjusted negative predictive value. Findings from this exploratory effort suggest that data-driven algorithms based on EHR elements hold promise to identify LD cases when detailed chart reviews are impractical. Further efforts may differentiate algorithms between confirmed and probable LD cases, pediatric and adult populations, and utilize text searching to improve accuracy.
- 12 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0349121
Open AccessExploring data-driven algorithms to identify Lyme disease cases in electronic health records
A tool capable of quickly and accurately identifying Lyme disease (LD) cases in endemic areas would have powerful applications in both research and public health. Using data from a single health system in an area with high LD incidence, we evaluated the feasibility and accuracy of data-driven algorithms to accurately identify LD cases based on easily extracted, structured data elements that are available in electronic health records (EHR). We used random forest and decision tree algorithms to explore the importance of various data elements and to investigate how different combinations of data elements accurately classified clinical events as either LD cases or non-cases. The data elements explored included patient demographics, International Classification of Diseases, 10 th Revision, (ICD) codes, LD laboratory tests and their results, and antibiotic prescription orders. Our best performing algorithm was a manually constructed decision tree that incorporated information from three presence/absence variables: an LD ICD code (A69.2x), a positive LD serology test, and a doxycycline order occurring within 30 days of either of the other two elements, which achieved 82% accuracy, 93% sensitivity, 60% adjusted positive predictive value, 68% specificity, and 91% adjusted negative predictive value. Findings from this exploratory effort suggest that data-driven algorithms based on EHR elements hold promise to identify LD cases when detailed chart reviews are impractical. Further efforts may differentiate algorithms between confirmed and probable LD cases, pediatric and adult populations, and utilize text searching to improve accuracy.
- Open Access
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e94921
Using Electronic Health Records to Enhance Lyme Disease Surveillance: Protocol for the SubLyme Network
Background: Lyme disease is the most common vector-borne illness in the United States. The limitations of traditional surveillance strategies for Lyme disease affect the ability to reliably track its burden and evaluate interventions. The US Centers for Disease Control and Prevention (CDC) established the Surveillance Based Lyme Disease Network (SubLyme) in September 2023 to strengthen Lyme disease surveillance and research using electronic health record (EHR) data. Objective: SubLyme has three primary objectives: (1) to establish and evaluate criteria for identifying Lyme disease cases in EHR data (ie, create computable phenotypes [CPs]) that can be scaled across diverse health systems, (2) to estimate Lyme disease incidence, and (3) to describe Lyme disease incidence by key demographics. Secondary objectives are to develop CPs that distinguish between acute and disseminated Lyme disease, identify clinical manifestations, and support future research efforts. This paper describes SubLyme, its structure, and its methods. Methods: SubLyme includes 5 health systems in 3 US regions with a high risk of Lyme disease: Geisinger, in Pennsylvania; Marshfield Clinic Health System, in Wisconsin; and Mass General Brigham, Tufts Medical Center, and MaineHealth in New England. The network is administered by a coordinating center (Westat) and the US CDC. SubLyme is evaluating the validity of EHR-based CP definitions for Lyme disease. CP performance is assessed by measuring sensitivity, specificity, positive predictive value, and negative predictive value against manually abstracted medical charts. Each site identified a cohort of patients with any Lyme disease element in their EHR (Lyme disease diagnosis code, Lyme disease laboratory test order, and Lyme-appropriate antibiotic order) during 2022 to 2023 and selected 500 charts for manual review as the gold standard against which CP performance was evaluated. SubLyme will use the Lyme disease CPs to generate incidence rates for Lyme disease overall and for various subgroups. Results: SubLyme identified 332,256 patients with at least 1 Lyme disease element in their record from more than 4.6 million patients. Of these patients, 55.6% (n=184,734) were female, 87.9% (n=292,053) were White, and 90.8% (n=301,688) were non-Hispanic. More than half of the patients only had a Lyme-appropriate medication order (n=177,425, 53.4%) and 35.8% (n=118,948) only had a Lyme disease test order. The most common combination was a medication order with a laboratory test order (n=22,926, 6.9%), followed by a combination of a diagnosis, test, and medication order (n=5316, 1.6%). Conclusions: SubLyme is well positioned to advance Lyme disease surveillance using EHR data across multiple health systems. The exploration of new surveillance methods in Lyme disease is critical as disease frequency increases and the geography expands. An EHR-based approach to surveillance has the potential to overcome challenges of current surveillance strategies and to accelerate Lyme disease research. International Registered Report Identifier (IRRID): DERR1-10.2196/94921
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e94921
Open AccessUsing Electronic Health Records to Enhance Lyme Disease Surveillance: Protocol for the SubLyme Network
Background: Lyme disease is the most common vector-borne illness in the United States. The limitations of traditional surveillance strategies for Lyme disease affect the ability to reliably track its burden and evaluate interventions. The US Centers for Disease Control and Prevention (CDC) established the Surveillance Based Lyme Disease Network (SubLyme) in September 2023 to strengthen Lyme disease surveillance and research using electronic health record (EHR) data. Objective: SubLyme has three primary objectives: (1) to establish and evaluate criteria for identifying Lyme disease cases in EHR data (ie, create computable phenotypes [CPs]) that can be scaled across diverse health systems, (2) to estimate Lyme disease incidence, and (3) to describe Lyme disease incidence by key demographics. Secondary objectives are to develop CPs that distinguish between acute and disseminated Lyme disease, identify clinical manifestations, and support future research efforts. This paper describes SubLyme, its structure, and its methods. Methods: SubLyme includes 5 health systems in 3 US regions with a high risk of Lyme disease: Geisinger, in Pennsylvania; Marshfield Clinic Health System, in Wisconsin; and Mass General Brigham, Tufts Medical Center, and MaineHealth in New England. The network is administered by a coordinating center (Westat) and the US CDC. SubLyme is evaluating the validity of EHR-based CP definitions for Lyme disease. CP performance is assessed by measuring sensitivity, specificity, positive predictive value, and negative predictive value against manually abstracted medical charts. Each site identified a cohort of patients with any Lyme disease element in their EHR (Lyme disease diagnosis code, Lyme disease laboratory test order, and Lyme-appropriate antibiotic order) during 2022 to 2023 and selected 500 charts for manual review as the gold standard against which CP performance was evaluated. SubLyme will use the Lyme disease CPs to generate incidence rates for Lyme disease overall and for various subgroups. Results: SubLyme identified 332,256 patients with at least 1 Lyme disease element in their record from more than 4.6 million patients. Of these patients, 55.6% (n=184,734) were female, 87.9% (n=292,053) were White, and 90.8% (n=301,688) were non-Hispanic. More than half of the patients only had a Lyme-appropriate medication order (n=177,425, 53.4%) and 35.8% (n=118,948) only had a Lyme disease test order. The most common combination was a medication order with a laboratory test order (n=22,926, 6.9%), followed by a combination of a diagnosis, test, and medication order (n=5316, 1.6%). Conclusions: SubLyme is well positioned to advance Lyme disease surveillance using EHR data across multiple health systems. The exploration of new surveillance methods in Lyme disease is critical as disease frequency increases and the geography expands. An EHR-based approach to surveillance has the potential to overcome challenges of current surveillance strategies and to accelerate Lyme disease research. International Registered Report Identifier (IRRID): DERR1-10.2196/94921
- Open Access
- 8 March 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Using Electronic Health Records to Enhance Lyme Disease Surveillance: Protocol for the SubLyme Network (Preprint)
BACKGROUND Lyme disease is the most common vector-borne illness in the United States. The limitations of traditional surveillance strategies for Lyme disease affect the ability to reliably track its burden and evaluate interventions. The US Centers for Disease Control and Prevention (CDC) established the Surveillance Based Lyme Disease Network (SubLyme) in September 2023 to strengthen Lyme disease surveillance and research using electronic health record (EHR) data. OBJECTIVE SubLyme has three primary objectives: (1) to establish and evaluate criteria for identifying Lyme disease cases in EHR data (ie, create computable phenotypes [CPs]) that can be scaled across diverse health systems, (2) to estimate Lyme disease incidence, and (3) to describe Lyme disease incidence by key demographics. Secondary objectives are to develop CPs that distinguish between acute and disseminated Lyme disease, identify clinical manifestations, and support future research efforts. This paper describes SubLyme, its structure, and its methods. METHODS SubLyme includes 5 health systems in 3 US regions with a high risk of Lyme disease: Geisinger, in Pennsylvania; Marshfield Clinic Health System, in Wisconsin; and Mass General Brigham, Tufts Medical Center, and MaineHealth in New England. The network is administered by a coordinating center (Westat) and the US CDC. SubLyme is evaluating the validity of EHR-based CP definitions for Lyme disease. CP performance is assessed by measuring sensitivity, specificity, positive predictive value, and negative predictive value against manually abstracted medical charts. Each site identified a cohort of patients with any Lyme disease element in their EHR (Lyme disease diagnosis code, Lyme disease laboratory test order, and Lyme-appropriate antibiotic order) during 2022 to 2023 and selected 500 charts for manual review as the gold standard against which CP performance was evaluated. SubLyme will use the Lyme disease CPs to generate incidence rates for Lyme disease overall and for various subgroups. RESULTS SubLyme identified 332,256 patients with at least 1 Lyme disease element in their record from more than 4.6 million patients. Of these patients, 55.6% (n=184,734) were female, 87.9% (n=292,053) were White, and 90.8% (n=301,688) were non-Hispanic. More than half of the patients only had a Lyme-appropriate medication order (n=177,425, 53.4%) and 35.8% (n=118,948) only had a Lyme disease test order. The most common combination was a medication order with a laboratory test order (n=22,926, 6.9%), followed by a combination of a diagnosis, test, and medication order (n=5316, 1.6%). CONCLUSIONS SubLyme is well positioned to advance Lyme disease surveillance using EHR data across multiple health systems. The exploration of new surveillance methods in Lyme disease is critical as disease frequency increases and the geography expands. An EHR-based approach to surveillance has the potential to overcome challenges of current surveillance strategies and to accelerate Lyme disease research. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/94921
- 8 March 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUsing Electronic Health Records to Enhance Lyme Disease Surveillance: Protocol for the SubLyme Network (Preprint)
BACKGROUND Lyme disease is the most common vector-borne illness in the United States. The limitations of traditional surveillance strategies for Lyme disease affect the ability to reliably track its burden and evaluate interventions. The US Centers for Disease Control and Prevention (CDC) established the Surveillance Based Lyme Disease Network (SubLyme) in September 2023 to strengthen Lyme disease surveillance and research using electronic health record (EHR) data. OBJECTIVE SubLyme has three primary objectives: (1) to establish and evaluate criteria for identifying Lyme disease cases in EHR data (ie, create computable phenotypes [CPs]) that can be scaled across diverse health systems, (2) to estimate Lyme disease incidence, and (3) to describe Lyme disease incidence by key demographics. Secondary objectives are to develop CPs that distinguish between acute and disseminated Lyme disease, identify clinical manifestations, and support future research efforts. This paper describes SubLyme, its structure, and its methods. METHODS SubLyme includes 5 health systems in 3 US regions with a high risk of Lyme disease: Geisinger, in Pennsylvania; Marshfield Clinic Health System, in Wisconsin; and Mass General Brigham, Tufts Medical Center, and MaineHealth in New England. The network is administered by a coordinating center (Westat) and the US CDC. SubLyme is evaluating the validity of EHR-based CP definitions for Lyme disease. CP performance is assessed by measuring sensitivity, specificity, positive predictive value, and negative predictive value against manually abstracted medical charts. Each site identified a cohort of patients with any Lyme disease element in their EHR (Lyme disease diagnosis code, Lyme disease laboratory test order, and Lyme-appropriate antibiotic order) during 2022 to 2023 and selected 500 charts for manual review as the gold standard against which CP performance was evaluated. SubLyme will use the Lyme disease CPs to generate incidence rates for Lyme disease overall and for various subgroups. RESULTS SubLyme identified 332,256 patients with at least 1 Lyme disease element in their record from more than 4.6 million patients. Of these patients, 55.6% (n=184,734) were female, 87.9% (n=292,053) were White, and 90.8% (n=301,688) were non-Hispanic. More than half of the patients only had a Lyme-appropriate medication order (n=177,425, 53.4%) and 35.8% (n=118,948) only had a Lyme disease test order. The most common combination was a medication order with a laboratory test order (n=22,926, 6.9%), followed by a combination of a diagnosis, test, and medication order (n=5316, 1.6%). CONCLUSIONS SubLyme is well positioned to advance Lyme disease surveillance using EHR data across multiple health systems. The exploration of new surveillance methods in Lyme disease is critical as disease frequency increases and the geography expands. An EHR-based approach to surveillance has the potential to overcome challenges of current surveillance strategies and to accelerate Lyme disease research. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/94921
- Open Access
- 20 November 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-9
Optimizing identification of Lyme disease diagnoses in commercial insurance claims data, United States, 2016–2019
Background: Commercial insurance claims data are a stable and consistent source of information on Lyme disease diagnoses in the United States and can contribute to our understanding of overall disease burden and the tracking of epidemiological trends. Algorithms consisting of diagnosis codes and antimicrobial treatment information have been used to identify Lyme disease diagnoses in claims data, but there might be opportunity to improve their accuracy. Methods: We developed three modified versions of our existing claims-based Lyme disease algorithm; each reflected refined criteria regarding antimicrobials prescribed and/or maximum days between diagnosis code and qualifying prescription claim. We applied each to a large national commercial claims database to identify Lyme disease diagnoses during 2016–2019. We then compared characteristics of Lyme disease diagnoses identified by each of the modified algorithms to those identified by our original algorithm to assess differences from expected trends in demographics, seasonality, and geography. Results: Observed differences in characteristics of patients with diagnoses identified by the three modified algorithms and our original algorithm were minimal, and differences in age and sex, in particular, were small enough that they could have been due to chance. However, one modified algorithm resulted in proportionally more diagnoses in men, during peak summer months, and in high-incidence jurisdictions, more closely reflecting epidemiological trends documented through public health surveillance. This algorithm limited treatment to only first-line recommended antimicrobials and shortened the timeframe between a Lyme disease diagnosis code and qualifying prescription claim. Conclusions: As compared to our original algorithm, a modified algorithm that limits the antimicrobials prescribed and shortens the timeframe between a diagnosis code and a qualifying prescription claim might more accurately identify Lyme disease diagnoses when utilizing insurance claims data for supplementary, routine identification and monitoring of Lyme disease diagnoses.
- 20 November 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-9
Open AccessOptimizing identification of Lyme disease diagnoses in commercial insurance claims data, United States, 2016–2019
Background: Commercial insurance claims data are a stable and consistent source of information on Lyme disease diagnoses in the United States and can contribute to our understanding of overall disease burden and the tracking of epidemiological trends. Algorithms consisting of diagnosis codes and antimicrobial treatment information have been used to identify Lyme disease diagnoses in claims data, but there might be opportunity to improve their accuracy. Methods: We developed three modified versions of our existing claims-based Lyme disease algorithm; each reflected refined criteria regarding antimicrobials prescribed and/or maximum days between diagnosis code and qualifying prescription claim. We applied each to a large national commercial claims database to identify Lyme disease diagnoses during 2016–2019. We then compared characteristics of Lyme disease diagnoses identified by each of the modified algorithms to those identified by our original algorithm to assess differences from expected trends in demographics, seasonality, and geography. Results: Observed differences in characteristics of patients with diagnoses identified by the three modified algorithms and our original algorithm were minimal, and differences in age and sex, in particular, were small enough that they could have been due to chance. However, one modified algorithm resulted in proportionally more diagnoses in men, during peak summer months, and in high-incidence jurisdictions, more closely reflecting epidemiological trends documented through public health surveillance. This algorithm limited treatment to only first-line recommended antimicrobials and shortened the timeframe between a Lyme disease diagnosis code and qualifying prescription claim. Conclusions: As compared to our original algorithm, a modified algorithm that limits the antimicrobials prescribed and shortens the timeframe between a diagnosis code and a qualifying prescription claim might more accurately identify Lyme disease diagnoses when utilizing insurance claims data for supplementary, routine identification and monitoring of Lyme disease diagnoses.
- 9 August 2023
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (1) , 111-121
Operational Considerations for Using Deer-Targeted 4-Poster Tick Control Devices in a Tick-borne Disease Endemic Community
Context: In the northeastern United States, recommendations to prevent diseases spread by black-legged ticks (Ixodes scapularis) and lone star ticks (Amblyomma americanum) often rely on individuals to use personal protection or yard-based strategies. The 4-Poster deer treatment stations (4-Posters) suppress tick populations by treating deer hosts with acaricide, potentially offering a community-wide approach for reducing tick-borne diseases in endemic areas. The 4-Poster deployment logistics in mainland community settings are not well documented but are needed for future public health tick control efforts. Program: As part of a public health research effort to design a population-based 4-Poster effectiveness study aimed at reducing tick-borne disease incidence, TickNET researchers partnered with the Town of Ridgefield (Connecticut) to understand the feasibility and operational logistics of deploying 4-Posters on public land within a residential community to inform future public health interventions by municipalities or vector control agencies. Implementation: We deployed three 4-Posters on a municipal property from July to December 2020 and used motion-activated cameras to record wildlife activity nearby. We documented per-device operational details, costs, materials consumed, and animal activity. Evaluation: Operation of 4-Posters was feasible, and device challenges were easily remedied. Deer visitation and heavy nontarget animal use were documented at all devices. Unexpectedly, monthly corn consumption was not correlated with monthly deer-view days. The monthly cost per device was US $1279 or US $305 per hectare with an average 21 minutes of weekly service time. Discussion: Use of 4-Posters by communities, public health agencies, or vector control programs may be a practicable addition to tick management programs in tick-borne disease endemic areas in the Northeast. Such programs should carefully consider local and state regulations, follow manufacturer and pesticide label guidelines, and include wildlife monitoring. High labor costs incurred in this project could be mitigated by training vector control agency or municipality staff to service 4-Posters.
- 9 August 2023
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (1) , 111-121
Operational Considerations for Using Deer-Targeted 4-Poster Tick Control Devices in a Tick-borne Disease Endemic Community
Context: In the northeastern United States, recommendations to prevent diseases spread by black-legged ticks (Ixodes scapularis) and lone star ticks (Amblyomma americanum) often rely on individuals to use personal protection or yard-based strategies. The 4-Poster deer treatment stations (4-Posters) suppress tick populations by treating deer hosts with acaricide, potentially offering a community-wide approach for reducing tick-borne diseases in endemic areas. The 4-Poster deployment logistics in mainland community settings are not well documented but are needed for future public health tick control efforts. Program: As part of a public health research effort to design a population-based 4-Poster effectiveness study aimed at reducing tick-borne disease incidence, TickNET researchers partnered with the Town of Ridgefield (Connecticut) to understand the feasibility and operational logistics of deploying 4-Posters on public land within a residential community to inform future public health interventions by municipalities or vector control agencies. Implementation: We deployed three 4-Posters on a municipal property from July to December 2020 and used motion-activated cameras to record wildlife activity nearby. We documented per-device operational details, costs, materials consumed, and animal activity. Evaluation: Operation of 4-Posters was feasible, and device challenges were easily remedied. Deer visitation and heavy nontarget animal use were documented at all devices. Unexpectedly, monthly corn consumption was not correlated with monthly deer-view days. The monthly cost per device was US $1279 or US $305 per hectare with an average 21 minutes of weekly service time. Discussion: Use of 4-Posters by communities, public health agencies, or vector control programs may be a practicable addition to tick management programs in tick-borne disease endemic areas in the Northeast. Such programs should carefully consider local and state regulations, follow manufacturer and pesticide label guidelines, and include wildlife monitoring. High labor costs incurred in this project could be mitigated by training vector control agency or municipality staff to service 4-Posters.
- Open Access
- 31 July 2023
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 14 (6) , 102231
Acceptability of 4-poster deer treatment devices for community-wide tick control among residents of high Lyme disease incidence counties in Connecticut and New York, USA
- 31 July 2023
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 14 (6) , 102231
Open AccessAcceptability of 4-poster deer treatment devices for community-wide tick control among residents of high Lyme disease incidence counties in Connecticut and New York, USA
- 7 February 2021
- Published by Wiley in Zoonoses and Public Health
- Vol. 68 (5) , 384-392
Human‐tick encounters as a measure of tickborne disease risk in lyme disease endemic areas
Entomological measures have long served as proxies for human risk of Lyme disease (LD) and other tickborne diseases (TBDs) in endemic areas of the United States, despite conflicting results regarding the correlation between these measures and human disease outcomes. Using data from a previous TBD intervention study in Connecticut, Maryland and New York, we evaluated whether human‐tick encounters can serve as an accurate proxy for risk of TBDs in areas where LD and other Ixodes scapularis‐transmitted infections are common. Among 2,590 households consisting of 4,210 individuals, experiencing a tick encounter was associated with an increased risk of both self‐reported (RR = 3.17, 95% CI: 2.05, 4.91) and verified TBD (RR = 2.60, 95% CI: 1.39, 4.84) at the household level. Household characteristics associated with experiencing any tick encounter were residence in Connecticut (aOR = 1.86, 95% CI: 1.38, 2.51) or New York (aOR = 1.66, 95% CI: 1.25, 2.22), head of household having a graduate level education (aOR = 1.46, 95% CI: 1.04, 2.08), owning a pet (aOR = 1.80, 95% CI: 1.46, 2.23) and a property size of 2 acres or larger (aOR = 2.30, 95% CI: 1.42, 3.70). Results for individual characteristics were similar to those for households. Future prevention studies in LD endemic areas should consider using human‐tick encounters as a robust proxy for TBD risk.
- 7 February 2021
- Published by Wiley in Zoonoses and Public Health
- Vol. 68 (5) , 384-392
Human‐tick encounters as a measure of tickborne disease risk in lyme disease endemic areas
Entomological measures have long served as proxies for human risk of Lyme disease (LD) and other tickborne diseases (TBDs) in endemic areas of the United States, despite conflicting results regarding the correlation between these measures and human disease outcomes. Using data from a previous TBD intervention study in Connecticut, Maryland and New York, we evaluated whether human‐tick encounters can serve as an accurate proxy for risk of TBDs in areas where LD and other Ixodes scapularis‐transmitted infections are common. Among 2,590 households consisting of 4,210 individuals, experiencing a tick encounter was associated with an increased risk of both self‐reported (RR = 3.17, 95% CI: 2.05, 4.91) and verified TBD (RR = 2.60, 95% CI: 1.39, 4.84) at the household level. Household characteristics associated with experiencing any tick encounter were residence in Connecticut (aOR = 1.86, 95% CI: 1.38, 2.51) or New York (aOR = 1.66, 95% CI: 1.25, 2.22), head of household having a graduate level education (aOR = 1.46, 95% CI: 1.04, 2.08), owning a pet (aOR = 1.80, 95% CI: 1.46, 2.23) and a property size of 2 acres or larger (aOR = 2.30, 95% CI: 1.42, 3.70). Results for individual characteristics were similar to those for households. Future prevention studies in LD endemic areas should consider using human‐tick encounters as a robust proxy for TBD risk.
- 1 January 2021
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 12 (1) , 101605
Experiences with tick exposure, Lyme disease, and use of personal prevention methods for tick bites among members of the U.S. population, 2013–2015
- 1 January 2021
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 12 (1) , 101605
Experiences with tick exposure, Lyme disease, and use of personal prevention methods for tick bites among members of the U.S. population, 2013–2015
- Top Cited Papers
- 1 July 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (7) , 1438-1446
Atypical Manifestations of Cat-Scratch Disease, United States, 2005–2014
Atypical disease is most common among children and leads to increased risk for hospitalization.
- 1 July 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (7) , 1438-1446
Top Cited PapersAtypical Manifestations of Cat-Scratch Disease, United States, 2005–2014
Atypical disease is most common among children and leads to increased risk for hospitalization.